Q2 EPS Estimates for Phio Pharmaceuticals Reduced by Sidoti

Posted by Stanley Muller on May 13th, 2026

Phio Pharmaceuticals Corp. (NASDAQ:PHIO – Free Report) – Sidoti decreased their Q2 2026 earnings per share estimates for Phio Pharmaceuticals in a report released on Monday, May 11th. Sidoti analyst A. Hantman now expects that the company will post earnings of ($0.37) per share for the quarter, down from their prior estimate of ($0.24). The consensus estimate for Phio Pharmaceuticals’ current full-year earnings is ($1.21) per share. Sidoti also issued estimates for Phio Pharmaceuticals’ Q3 2026 earnings at ($0.31) EPS, Q4 2026 earnings at ($0.34) EPS, FY2026 earnings at ($1.35) EPS, Q1 2027 earnings at ($0.20) EPS, Q2 2027 earnings at ($0.22) EPS, Q3 2027 earnings at ($0.24) EPS, Q4 2027 earnings at ($0.25) EPS and FY2027 earnings at ($0.91) EPS.

Phio Pharmaceuticals (NASDAQ:PHIO – Get Free Report) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($0.34) EPS for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.10).

Other research analysts also recently issued research reports about the stock. HC Wainwright reaffirmed a “buy” rating and issued a $14.00 target price on shares of Phio Pharmaceuticals in a report on Tuesday, February 10th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Phio Pharmaceuticals in a research note on Tuesday, April 21st. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Hold” and an average target price of $14.00.

View Our Latest Report on PHIO

Phio Pharmaceuticals Stock Performance

NASDAQ:PHIO opened at $1.10 on Wednesday. The stock has a 50-day simple moving average of $1.21 and a two-hundred day simple moving average of $1.24. The firm has a market capitalization of $12.78 million, a PE ratio of -0.80 and a beta of 0.84. Phio Pharmaceuticals has a 52-week low of $0.81 and a 52-week high of $4.19.

Institutional Trading of Phio Pharmaceuticals

An institutional investor recently raised its position in Phio Pharmaceuticals stock. Geode Capital Management LLC raised its stake in Phio Pharmaceuticals Corp. (NASDAQ:PHIO – Free Report) by 60.0% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 92,638 shares of the company’s stock after buying an additional 34,732 shares during the period. Geode Capital Management LLC owned about 0.86% of Phio Pharmaceuticals worth $97,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 57.31% of the stock is owned by institutional investors.

About Phio Pharmaceuticals

(Get Free Report)

Phio Pharmaceuticals, Inc (NASDAQ: PHIO) is a clinical‐stage biotechnology company focused on the discovery and development of dual RNA interference (RNAi) therapeutics. Utilizing its proprietary Transitional RNAi (TRiMTM) platform, Phio aims to simultaneously silence multiple gene targets to achieve enhanced therapeutic activity. The company’s core mission is to advance next‐generation RNAi compounds with potential applications in oncology and immuno‐oncology.

Phio’s TRiMTM platform is designed around the delivery of synthetic, double‐stranded RNA duplexes that can be engineered to target specific combinations of genes implicated in tumor growth and immune evasion.